Insights & Resources

J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.

KPMG has released their 2024 biopharma report detailing the challenges and opportunities for pharma companies moving forward into the new year.

Beneficial Ownership Information (BOI) reporting, a mandate of the Corporate Transparency Act (CTA), continues to be complicated.

For venture capital fund managers, understanding the Qualified Small Business Stock (QSBS) exemption presents a lucrative opportunity. Learn more in this overview.

FinCEN suspends Corporate Transparency Act reporting deadlines following order granting a preliminary injunction in federal district court in Texas.

Selecting an entity type in real estate is often decided by issues like tax flexibility. Here are some of the key considerations to keep in mind.

The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.

The biopharma industry has experienced a resurgence the first part of 2024. J.P. Morgan’s Q2 report shares critical insights into the future of the industry.

The initial enthusiasm for ESG in financial services was met with increased scrutiny, but the underlying ESG principles continue to hold sway.

AI is revolutionizing industries, but misleading claims are rampant. Learn how the SEC combats AI washing and the importance of transparency for investment advisers.

Unravel life sciences industry complexities, and discover the differences between FDA special review designations like Fast Track, Priority Review and Breakthrough.

The credit is aimed at bolstering and incentivizing the emerging biotechnology sector to create jobs and invest in NYC and is available 1/1/23-1/1/26.